$RHE
Regional Health Properties Inc

2023 Q2 Form 10-Q Financial Statement

#000095017023021971 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $4.598M $3.906M
YoY Change -43.19% -41.25%
Cost Of Revenue $2.159M $2.537M
YoY Change -48.86% 8.28%
Gross Profit $2.439M $1.369M
YoY Change -36.99% -68.2%
Gross Profit Margin 53.04% 35.05%
Selling, General & Admin $1.330M $1.512M
YoY Change -57.98% -67.84%
% of Gross Profit 54.53% 110.45%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $702.0K $510.0K
YoY Change 15.84% -16.8%
% of Gross Profit 28.78% 37.25%
Operating Expenses $4.412M $4.651M
YoY Change -48.83% -41.77%
Operating Profit $186.0K -$745.0K
YoY Change -135.16% -44.36%
Interest Expense $679.0K $680.0K
YoY Change 6.26% 4.13%
% of Operating Profit 365.05%
Other Income/Expense, Net -$871.0K -$1.247M
YoY Change 9.42% -21.47%
Pretax Income -$685.0K -$1.992M
YoY Change -48.3% -31.94%
Income Tax
% Of Pretax Income
Net Earnings -$685.0K -$1.992M
YoY Change -48.3% -31.94%
Net Earnings / Revenue -14.9% -51.0%
Basic Earnings Per Share $22.68 -$2.28
Diluted Earnings Per Share $22.68 -$2.28
COMMON SHARES
Basic Shares Outstanding 1.883M 1.883M
Diluted Shares Outstanding 1.883M 1.862M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.926M $2.803M
YoY Change -26.38% -38.19%
Cash & Equivalents $1.900M $2.800M
Short-Term Investments
Other Short-Term Assets $4.176M $3.511M
YoY Change 0.97% -11.65%
Inventory
Prepaid Expenses
Receivables $3.023M $2.915M
Other Receivables $772.0K $804.0K
Total Short-Term Assets $9.897M $10.03M
YoY Change -13.14% -18.17%
LONG-TERM ASSETS
Property, Plant & Equipment $46.27M $46.11M
YoY Change -5.72% -7.04%
Goodwill $1.585M $1.585M
YoY Change 0.0% 0.0%
Intangibles $12.06M $12.17M
YoY Change -3.51% -3.48%
Long-Term Investments
YoY Change
Other Assets $2.939M
YoY Change 638.44%
Total Long-Term Assets $55.96M $55.92M
YoY Change -36.54% -38.07%
TOTAL ASSETS
Total Short-Term Assets $9.897M $10.03M
Total Long-Term Assets $55.96M $55.92M
Total Assets $65.85M $65.95M
YoY Change -33.86% -35.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.036M $3.159M
YoY Change -31.45% -29.89%
Accrued Expenses $4.832M $5.254M
YoY Change -11.24% 5.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.868M $8.413M
YoY Change -20.31% -11.16%
LONG-TERM LIABILITIES
Long-Term Debt $52.03M $51.51M
YoY Change -1.21% -2.58%
Other Long-Term Liabilities $4.679M $4.222M
YoY Change -84.81% -87.08%
Total Long-Term Liabilities $52.03M $51.51M
YoY Change -1.21% -2.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.868M $8.413M
Total Long-Term Liabilities $52.03M $51.51M
Total Liabilities $64.58M $64.15M
YoY Change -30.82% -32.49%
SHAREHOLDERS EQUITY
Retained Earnings -$80.69M -$123.4M
YoY Change -32.07%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.275M $1.805M
YoY Change
Total Liabilities & Shareholders Equity $65.85M $65.95M
YoY Change -33.86% -35.69%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$685.0K -$1.992M
YoY Change -48.3% -31.94%
Depreciation, Depletion And Amortization $702.0K $510.0K
YoY Change 15.84% -16.8%
Cash From Operating Activities $358.0K $2.600M
YoY Change -129.37% -262.5%
INVESTING ACTIVITIES
Capital Expenditures $852.0K $2.000K
YoY Change -1283.33% -97.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$852.0K -$2.000K
YoY Change 1083.33% -97.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -460.0K -685.0K
YoY Change -34.38% 1.78%
NET CHANGE
Cash From Operating Activities 358.0K 2.600M
Cash From Investing Activities -852.0K -2.000K
Cash From Financing Activities -460.0K -685.0K
Net Change In Cash -954.0K 1.910M
YoY Change -52.11% -219.38%
FREE CASH FLOW
Cash From Operating Activities $358.0K $2.600M
Capital Expenditures $852.0K $2.000K
Free Cash Flow -$494.0K $2.598M
YoY Change -56.93% -254.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
REGIONAL HEALTH PROPERTIES, INC.
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001004724
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-33135
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
GA
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-5166048
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
454 Satellite Boulevard NW
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Suwanee
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30024
CY2023Q1 dei City Area Code
CityAreaCode
678
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
869-5116
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1883028
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46109000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46611000
CY2023Q1 us-gaap Cash
Cash
2803000
CY2022Q4 us-gaap Cash
Cash
843000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
3016000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
3066000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1204000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1298000
CY2023Q1 us-gaap Receivables From Customers
ReceivablesFromCustomers
2915000
CY2022Q4 us-gaap Receivables From Customers
ReceivablesFromCustomers
6289000
CY2023Q1 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
495000
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
746000
CY2023Q1 us-gaap Notes Receivable Net
NotesReceivableNet
804000
CY2022Q4 us-gaap Notes Receivable Net
NotesReceivableNet
1099000
CY2023Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2471000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2471000
CY2023Q1 rhe Finite Lived Intangible Assets Lease Rights Net
FiniteLivedIntangibleAssetsLeaseRightsNet
104000
CY2022Q4 rhe Finite Lived Intangible Assets Lease Rights Net
FiniteLivedIntangibleAssetsLeaseRightsNet
110000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2763000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2848000
CY2023Q1 us-gaap Goodwill
Goodwill
1585000
CY2022Q4 us-gaap Goodwill
Goodwill
1585000
CY2023Q1 us-gaap Deferred Rent Receivables Net
DeferredRentReceivablesNet
2887000
CY2022Q4 us-gaap Deferred Rent Receivables Net
DeferredRentReceivablesNet
2912000
CY2023Q1 us-gaap Assets
Assets
65952000
CY2022Q4 us-gaap Assets
Assets
68580000
CY2023Q1 us-gaap Senior Long Term Notes
SeniorLongTermNotes
44857000
CY2022Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
45163000
CY2023Q1 us-gaap Longterm Transition Bond Current And Noncurrent
LongtermTransitionBondCurrentAndNoncurrent
6122000
CY2022Q4 us-gaap Longterm Transition Bond Current And Noncurrent
LongtermTransitionBondCurrentAndNoncurrent
6120000
CY2023Q1 us-gaap Other Long Term Debt
OtherLongTermDebt
533000
CY2022Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
895000
CY2023Q1 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
3159000
CY2022Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
3293000
CY2023Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
5254000
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
5036000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3137000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3226000
CY2023Q1 us-gaap Other Liabilities
OtherLiabilities
1085000
CY2022Q4 us-gaap Other Liabilities
OtherLiabilities
1131000
CY2023Q1 us-gaap Liabilities
Liabilities
64147000
CY2022Q4 us-gaap Liabilities
Liabilities
64864000
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
55000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
55000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1884000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1775000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1874000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1775000
CY2023Q1 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
62783000
CY2022Q4 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
62702000
CY2022Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2023Q1 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2812000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2812000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2812000
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2812000
CY2023Q1 us-gaap Preferred Stock Redemption Amount
PreferredStockRedemptionAmount
70288000
CY2022Q4 us-gaap Preferred Stock Redemption Amount
PreferredStockRedemptionAmount
70288000
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
62423000
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
62423000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123401000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121409000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1805000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3716000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
65952000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
68580000
CY2023Q1 us-gaap Revenues
Revenues
3906000
CY2022Q1 us-gaap Revenues
Revenues
6648000
CY2023Q1 rhe Patient Care Expense
PatientCareExpense
2537000
CY2022Q1 rhe Patient Care Expense
PatientCareExpense
2343000
CY2023Q1 rhe Facility Rent Expense
FacilityRentExpense
149000
CY2022Q1 rhe Facility Rent Expense
FacilityRentExpense
1639000
CY2023Q1 rhe Cost Of Management Fees
CostOfManagementFees
141000
CY2022Q1 rhe Cost Of Management Fees
CostOfManagementFees
179000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
510000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
613000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1206000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1123000
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
16000
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1761000
CY2023Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
92000
CY2022Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
329000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4651000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
7987000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-745000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1339000
CY2023Q1 us-gaap Interest Expense
InterestExpense
680000
CY2022Q1 us-gaap Interest Expense
InterestExpense
653000
CY2023Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
567000
CY2022Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
935000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1247000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1588000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-1992000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2927000
CY2023Q1 rhe Preferred Stock Dividends Undeclared
PreferredStockDividendsUndeclared
2249000
CY2022Q1 rhe Preferred Stock Dividends Undeclared
PreferredStockDividendsUndeclared
2250000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4241000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5177000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.28
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.28
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.89
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.89
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1862000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1862000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1790000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1790000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3716000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
81000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-1992000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1805000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10396000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
111000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-46000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2927000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7534000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-1992000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2927000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
510000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
613000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
81000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
111000
CY2023Q1 rhe Rent Expense Less Than In Excess Of Cash Paid
RentExpenseLessThanInExcessOfCashPaid
-4000
CY2022Q1 rhe Rent Expense Less Than In Excess Of Cash Paid
RentExpenseLessThanInExcessOfCashPaid
60000
CY2023Q1 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
26000
CY2022Q1 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
-440000
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
19000
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
22000
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
16000
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1761000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3357000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1696000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-546000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-94000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-107000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
950000
CY2023Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
145000
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-127000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2597000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1579000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
80000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-80000
CY2023Q1 us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
322000
CY2022Q1 us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
408000
CY2023Q1 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
363000
CY2022Q1 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
219000
CY2022Q1 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
46000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-685000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-673000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1910000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2332000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3909000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9848000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5819000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7516000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
650000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
633000
CY2022Q1 rhe Vendor Financed Insurance
VendorFinancedInsurance
606000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
500000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates.</span></p>
CY2023Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain reclassifications have been made to the amounts in prior periods in order to conform to the current period's presentation. A reclassification has been made to the stock balances on the consolidated statement of stockholders’ equity in prior periods in order to conform to the current period's presentation.</span></p>
CY2023Q1 rhe Penalty For Service Contract Non Performance
PenaltyForServiceContractNonPerformance
50000
CY2023Q1 rhe Percentage Of Reserve For Patient Care Receivables
PercentageOfReserveForPatientCareReceivables
0.015
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2900000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6300000
CY2023Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
4119000
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
7587000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1204000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1298000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2915000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6289000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
700000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-200000
CY2023Q1 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
3159000
CY2022Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
3293000
CY2023Q1 us-gaap Other Liabilities
OtherLiabilities
1100000
CY2022Q4 us-gaap Other Liabilities
OtherLiabilities
1100000
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0385
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
48000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
52000
CY2023Q1 rhe Antidilutive Securities Excluded From Computation Of Earnings Per Share Intrinsic Value
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareIntrinsicValue
0
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2800000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2600000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
51500000
CY2023Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
1100000
CY2023Q1 rhe Long Term Debt Maturities Repayments Of Principal In Next Twelve Months Subject To Non Default In Payments
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonthsSubjectToNonDefaultInPayments
1500000
CY2023Q1 us-gaap Cash
Cash
2803000
CY2022Q4 us-gaap Cash
Cash
843000
CY2023Q1 us-gaap Replacement Reserve Escrow
ReplacementReserveEscrow
2119000
CY2022Q4 us-gaap Replacement Reserve Escrow
ReplacementReserveEscrow
2155000
CY2023Q1 rhe Escrow Deposit Current
EscrowDepositCurrent
407000
CY2022Q4 rhe Escrow Deposit Current
EscrowDepositCurrent
459000
CY2023Q1 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
317000
CY2022Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
317000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
3016000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
3066000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5819000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3909000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
67983000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
68327000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21874000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21716000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46109000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46611000
CY2023Q1 us-gaap Land Improvements
LandImprovements
100000
CY2023Q1 us-gaap Depreciation
Depreciation
400000
CY2022Q1 us-gaap Depreciation
Depreciation
503000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
110000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
110000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
510000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
613000
CY2022Q4 rhe Finite And Indefinite Lived Intangible Assets Gross
FiniteAndIndefiniteLivedIntangibleAssetsGross
16953000
CY2022Q4 us-gaap Goodwill Gross
GoodwillGross
1585000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4678000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12275000
CY2022Q4 us-gaap Goodwill
Goodwill
1585000
CY2023Q1 rhe Finite And Indefinite Lived Intangible Assets Gross
FiniteAndIndefiniteLivedIntangibleAssetsGross
16953000
CY2023Q1 us-gaap Goodwill Gross
GoodwillGross
1585000
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4788000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12165000
CY2023Q1 us-gaap Goodwill
Goodwill
1585000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
110000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
110000
CY2023Q1 rhe Operating Leases Number Of Skilled Nursing Facilities Leased
OperatingLeasesNumberOfSkilledNursingFacilitiesLeased
1
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y1M6D
CY2023Q1 rhe Lessee Operating Lease Liability Future Rental Payments Due Year One
LesseeOperatingLeaseLiabilityFutureRentalPaymentsDueYearOne
480000
CY2023Q1 rhe Lessee Operating Lease Accretion Of Lease Liability Due Year One
LesseeOperatingLeaseAccretionOfLeaseLiabilityDueYearOne
28000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
452000
CY2023Q1 rhe Lessee Operating Lease Liability Future Rental Payments Due Year Two
LesseeOperatingLeaseLiabilityFutureRentalPaymentsDueYearTwo
633000
CY2023Q1 rhe Lessee Operating Lease Accretion Of Lease Liability Due Year Two
LesseeOperatingLeaseAccretionOfLeaseLiabilityDueYearTwo
62000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
571000
CY2023Q1 rhe Lessee Operating Lease Liability Future Rental Payments Due Year Three
LesseeOperatingLeaseLiabilityFutureRentalPaymentsDueYearThree
645000
CY2023Q1 rhe Lessee Operating Lease Accretion Of Lease Liability Due Year Three
LesseeOperatingLeaseAccretionOfLeaseLiabilityDueYearThree
107000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
538000
CY2023Q1 rhe Lessee Operating Lease Liability Future Rental Payments Due Year Four
LesseeOperatingLeaseLiabilityFutureRentalPaymentsDueYearFour
658000
CY2023Q1 rhe Lessee Operating Lease Accretion Of Lease Liability Due Year Four
LesseeOperatingLeaseAccretionOfLeaseLiabilityDueYearFour
152000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
507000
CY2023Q1 rhe Lessee Operating Lease Liability Future Rental Payments Due Year Five
LesseeOperatingLeaseLiabilityFutureRentalPaymentsDueYearFive
671000
CY2023Q1 rhe Lessee Operating Lease Accretion Of Lease Liability Due Year Five
LesseeOperatingLeaseAccretionOfLeaseLiabilityDueYearFive
194000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
477000
CY2023Q1 rhe Lessee Operating Lease Liability Future Rental Payments Due After Year Five
LesseeOperatingLeaseLiabilityFutureRentalPaymentsDueAfterYearFive
914000
CY2023Q1 rhe Lessee Operating Lease Accretion Of Lease Liability Due After Year Five
LesseeOperatingLeaseAccretionOfLeaseLiabilityDueAfterYearFive
322000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
593000
CY2023Q1 rhe Lessee Operating Lease Liability Future Rental Payments
LesseeOperatingLeaseLiabilityFutureRentalPayments
4002000
CY2023Q1 rhe Lessee Operating Lease Accretion Of Lease Liability
LesseeOperatingLeaseAccretionOfLeaseLiability
865000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3137000
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0385
CY2023Q1 rhe Number Of Owned Facilities Lessor
NumberOfOwnedFacilitiesLessor
9
CY2023Q1 rhe Number Of Owned Facilities
NumberOfOwnedFacilities
11
CY2023Q1 rhe Number Of Owned Facilities Sub Lessor
NumberOfOwnedFacilitiesSubLessor
1
CY2023Q1 rhe Weighted Average Remaining Lease Term Facilities Lessor
WeightedAverageRemainingLeaseTermFacilitiesLessor
P6Y
CY2023Q1 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
1708000
CY2022Q1 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
4065000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3906000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6648000
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
4698000
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
6187000
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
6034000
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
5362000
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received Five Years
LessorOperatingLeasePaymentsToBeReceivedFiveYears
5445000
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received Thereafter
LessorOperatingLeasePaymentsToBeReceivedThereafter
11605000
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
39330000
CY2023Q1 rhe Accrued Payroll Related Expenses Current
AccruedPayrollRelatedExpensesCurrent
433000
CY2022Q4 rhe Accrued Payroll Related Expenses Current
AccruedPayrollRelatedExpensesCurrent
539000
CY2023Q1 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
2502000
CY2022Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
2428000
CY2023Q1 us-gaap Self Insurance Reserve Current
SelfInsuranceReserveCurrent
66000
CY2022Q4 us-gaap Self Insurance Reserve Current
SelfInsuranceReserveCurrent
80000
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
223000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
210000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
43000
CY2023Q1 rhe Medicaid Overpayment Healthcare Services
MedicaidOverpaymentHealthcareServices
52000
CY2022Q4 rhe Medicaid Overpayment Healthcare Services
MedicaidOverpaymentHealthcareServices
169000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1978000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1567000
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5254000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5036000
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
52635000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
53302000
CY2023Q1 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
1005000
CY2022Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
1005000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
118000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
119000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
51512000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
52178000
CY2023Q1 rhe Debt Instrument Number Of Credit Related Instruments
DebtInstrumentNumberOfCreditRelatedInstruments
16
CY2023Q1 rhe Patient Care Expense
PatientCareExpense
2537000
CY2022Q1 rhe Patient Care Expense
PatientCareExpense
2343000
CY2023Q1 rhe Facility Rent Expense
FacilityRentExpense
149000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths
1477000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
1597000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree
2175000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour
8540000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive
1435000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive
37412000
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
52635000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
118000
CY2023Q1 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
1005000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
51512000
CY2023Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2022Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2023Q1 rhe Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
81000
CY2022Q1 rhe Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
65000
CY2023Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
0
CY2022Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
0
CY2022Q1 rhe Facility Rent Expense
FacilityRentExpense
1639000
CY2023Q1 rhe Cost Of Management Fees
CostOfManagementFees
141000
CY2022Q1 rhe Cost Of Management Fees
CostOfManagementFees
179000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
510000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
613000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1206000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1123000
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
16000
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1761000
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
37000
CY2023Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y9M18D
CY2023Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
18.70
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
37000
CY2023Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
18.70
CY2023Q1 us-gaap Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
10
CY2023Q1 us-gaap Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
10
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2023Q1 us-gaap Additional Information About Entitys Reportable Segments
AdditionalInformationAboutEntitysReportableSegments
(i) Real Estate Services, which consists of the leasing and subleasing of long-term care and senior living facilities to third-party tenants, including the Company's management of three facilities on behalf of third-party owners; and (ii) Healthcare Services, which consists of the operation of the Meadowood and Glenvue facilities.
CY2023Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
92000
CY2022Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
329000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4651000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
7987000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-745000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1339000
CY2023Q1 us-gaap Interest Expense
InterestExpense
680000
CY2022Q1 us-gaap Interest Expense
InterestExpense
653000
CY2023Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
567000
CY2022Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
935000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1247000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1588000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1992000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2927000

Files In Submission

Name View Source Status
0000950170-23-021971-index-headers.html Edgar Link pending
0000950170-23-021971-index.html Edgar Link pending
0000950170-23-021971.txt Edgar Link pending
0000950170-23-021971-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rhe-20230331.htm Edgar Link pending
rhe-20230331.xsd Edgar Link pending
rhe-ex31_1.htm Edgar Link pending
rhe-ex31_2.htm Edgar Link pending
rhe-ex32_1.htm Edgar Link pending
rhe-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending
rhe-20230331_cal.xml Edgar Link unprocessable
rhe-20230331_def.xml Edgar Link unprocessable
rhe-20230331_lab.xml Edgar Link unprocessable
rhe-20230331_pre.xml Edgar Link unprocessable
rhe-20230331_htm.xml Edgar Link completed